Todays PR again suggest Brilacidin's mechanism of action is the same for viruses as bacteria, it attaches to the "pathogens" cell wall and disrupts it.
It also answers a confusing question about vaccines. The last PR suggested Brilacidin has a vaccine. Todays PR suggests disrupting the virus cell wall could enhance the development of new drugs and vaccines , presumably by exposing more antigens.
"Brilacidin is a compelling investigational drug for COVID-19 due to its unique qualities to mimic the human innate immune system and Mechanism of Action that includes disruption of the membrane of pathogens, leading to cell death. Throughout laboratory and clinical studies, Brilacidin has demonstrated potent activity against Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), and coverage against Gram-negative bacteria. Research supports the ability of Brilacidin to swiftly penetrate a peptidoglycan layer in these difficult bacteria, which is key to rapid pathogen destruction and decreases the likelihood of drug resistance emerging.
The ability to penetrate cell walls engenders confidence in this opportunity to meet an urgent medical need in treating coronaviruses like COVID-19. COVID-19 is an “enveloped” virus, meaning it has a glycoprotein envelope surrounding its nucleocapsid. More succinctly, it has a lipid envelope derived from the host cell membranes studded with crown-like projections from which it is named."
"
"Penetrating the COVID-19 envelope could prove beneficial in designing a new drug or vaccine against the virus, although this would have to be confirmed through extensive laboratory and clinical research."
GLTA Farrell
Market Data 
Markets 
AI
